SUMMARY Burkitt lymphoma (BL) is a disease of predominantly young population, while in the elderly it occurs as a rare neoplasm. Elderly patients (age >60 years) represent a significant problem because of the inability to apply effective aggressive chemiotherapy in these cases. The risk of induction death is very high and unacceptible. Mainly, palliative treatments are applied, whose goal is not curing but maintaining the quality of life. We present the case of a person 75 years old with a diagnosis of sporadic, typical BL treated with CHOP+R in the induction therapy with excellent response but rapid progression after the abolition of rituximab. In discussion, the authors are looking for relevant data on the therapeutic approach in BL in the elderly.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.